Clinical trials: Immunoglobulin E-Mediated Allergic Disorder
- Condition Immunoglobulin E-Mediated Allergic Disorder
- Funder type Industry (pharma, biotech, devices)
Type I Hypersensitivity
Efficacy and Safety/Tolerability of Ragweed MATA MPL
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis…
- Trial name
- NCT00423787
- Testing
- Ragweed MATA MPL
- Where
- 76 sites in United States, Canada
- Volunteers
- 993 people
- Sponsor
- Allergy Therapeutics
Peanut Allergy
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
The objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize…
- Trial name
- VIPES (NCT01675882)
- Testing
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- DBV Technologies
Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy.
- Trial name
- NCT06369467
- Testing
- linvoseltamab, dupilumab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Regeneron Pharmaceuticals
Type I Hypersensitivity
Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis
Tree MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to Tree (birch, alder, hazel) pollen (hay fever).
- Trial name
- NCT00387478
- Testing
- Tree MATA MPL or Tree MATA
- Where
- Canada
- Volunteers
- 121 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Safety and tolerability of different dose combinations of MPL and grass pollen allergen and to identify the highest combinations of MPL and grass pollen allergen which is safe.
- Trial name
- NCT00241410
- Testing
- OralvacB2MPL
- Where
- Germany
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
The safety and tolerability of tyrosine adsorbed ragweed pollen allergoid with monophosphoryl lipid A (MPL) was planned to be evaluated.
- Trial name
- NCT00109759
- Testing
- RagweedMATAMPL
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Cow's Milk Allergy
Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.
The aim of this interventional study is to assess the hypoallergenicity of a new formula in infants having a cow milk allergy (CMA), whatever the type of CMA, meaning in both IgE-mediated and non-IgE-mediated CMA patients.
- Trial name
- MERLIN (NCT06481280)
- Testing
- Test Formula
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 70 people
- Sponsor
- United Pharmaceuticals
Cow Milk Allergy
Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins
The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in…
- Trial name
- NCT03557671
- Testing
- rice formula
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 72 people
- Sponsor
- United Pharmaceuticals
Type I Hypersensitivity
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen.
- Trial name
- NCT00104377
- Testing
- Grass MATA MPL
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Tree MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00107705
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118625
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy
Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen (hay fever).
- Trial name
- NCT00110786
- Testing
- Ragweed MATAMPL
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- Allergy Therapeutics